Drugs / [90Y]Y-PentixaTher
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06132737 | Nov 2023 → Sep 2027 expected | central nervous system non-hodgkin lymphoma | Pentixapharm AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-08 | Pentixapharm AG | Regulatory PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma pentixapharm.com ↗
PentixaPharm GmbH, a developer of innovative radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start PTT101, its open-label dose escalation study to evaluate the safety, tolerability, biodistribution and efficacy of PentixaTher. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-08 | Pentixapharm AG | PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma pentixapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [90Y]Y-PentixaTher | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132737 ↗ |
| Route | Intravenous | “which will be administered intravenously.” NCT06132737 ↗ |